FDA Grants Breakthrough Therapy Status to Arrowhead’s Plozasiran for Severe High Triglycerides

Arrowhead Pharmaceuticals received FDA Breakthrough Therapy designation for plozasiran, a promising treatment aimed at lowering dangerously high triglyceride levels in adults with severe hypertriglyceridemia.